Edition:
India

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

13.35USD
25 Apr 2018
Change (% chg)

$-0.06 (-0.45%)
Prev Close
$13.41
Open
$13.39
Day's High
$13.44
Day's Low
$13.13
Volume
361,396
Avg. Vol
732,724
52-wk High
$49.08
52-wk Low
$13.05

Select another date:

Tue, Apr 17 2018

BRIEF-Mallinckrodt Announces $300 Million Debt Repayment

* MALLINCKRODT PLC - COMPANY REPAYS DEBT MATURING APRIL 2018 WITH CASH ON HAND

BRIEF-Mallinckrodt Names Paul Carter, Anne Whitaker To Its Board Of Directors

* MALLINCKRODT NAMES PAUL R. CARTER, ANNE C. WHITAKER TO ITS BOARD OF DIRECTORS

BRIEF-Angus Russell To Succeed Melvin Booth As Mallinckrodt Board Chairman In May 2018

* ANGUS RUSSELL TO SUCCEED MELVIN BOOTH AS MALLINCKRODT CHAIRMAN OF THE BOARD IN MAY 2018

BRIEF-Evoke Announces Agreement With Mallinckrodt To Amend Milestone Payments

* EVOKE ANNOUNCES AGREEMENT WITH MALLINCKRODT TO AMEND MILESTONE PAYMENTS

U.S. subpoenas Mallinckrodt for information on opioid painkillers

Pharmaceutical company Mallinckrodt Plc said on Tuesday it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to generic drugs it produces that contain the opioid painkiller oxymorphone.

UPDATE 1-U.S. subpoenas Mallinckrodt for information on opioid painkillers

Feb 27 Pharmaceutical company Mallinckrodt Plc said on Tuesday it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to generic drugs it produces that contain the opioid painkiller oxymorphone.

U.S. subpoenas Mallinckrodt for information on opioid painkillers

Feb 27 Pharmaceutical company Mallinckrodt Plc on Tuesday said that it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to generic drugs it produces that contain the opioid painkiller oxymorphone.

BRIEF-Mallinckrodt Plc Reports Fourth Quarter Adj. EPS Of $2.01

* REPORTS FOURTH QUARTER AND FISCAL 2017 RESULTS, ANNOUNCES 2018 GUIDANCE AND SETS 2018 STRATEGIC PRIORITIES

BRIEF-Mallinckrodt Receives FDA Acceptance Of Stannsoporfin New Drug Application Filing

* MALLINCKRODT RECEIVES FDA ACCEPTANCE OF STANNSOPORFIN NEW DRUG APPLICATION FILING

BRIEF-Paulson & Co Cuts Share Stake In Mallinckrodt PLC

* PAULSON & CO CUTS SHARE STAKE IN MALLINCKRODT PLC TO 3.7 MILLION SHARES FROM 6.6 MILLION SHARES - SEC FILING

Select another date: